A Cohort Study on Biomarkers of Hypertension in Guangdong Province(GDP Study)

January 10, 2020 updated by: Guangdong Provincial People's Hospital

Establishing Biobank in a Cohort Study for Hypertensive Patients in Guangdong Province(GDP Study)

Hypertension is the most common chronic diseases and a most important risk factor for cardiovascular and cerebrovascular diseases, and also a substantial public health problem. The purpose of the study is to investigate the association between biomarkers and adverse outcomes in patients with hypertension.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Study population includes subjects who are hypertension, of any race or ethnicity, 18 or older years of age, and have provided written informed consent to provide whole blood specimens at one or more study visits.

Physical examination, questionnaire survey and biological sample collection will be conducted at baseline and the incidence of all-cause and cardiovascular mortality will be investigated during follow-up.

Study Type

Observational

Enrollment (Anticipated)

50000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: HUANG Yu qing, MD
  • Phone Number: +8613172054256
  • Email: hyq513@126.com

Study Locations

  • China
    • Guangdong
      • Guangzhou, Guangdong, China, 510080
        • Recruiting
        • Guangdong Provincial People's Hospital
        • Contact:
      • Guangzhou, Guangdong, China, 510100
        • Recruiting
        • Guangdong Cardiovascular Institute
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with hypertension

Description

Inclusion Criteria:

  • ≥18 years old
  • In accordance with the diagnosis of hypertension (including Blood pressure ≥140/90mmHg and/or taking antihypertensive drugs and/or self-reported hypertension)

Exclusion Criteria:

  • <18 years old
  • Unsigned informed consent
  • Pregnant Women and Lactation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
All-Cause Mortality
Time Frame: From date of inclusion until the date of death from any cause, assessed up to 1 year
All-cause mortality was confirmed through a combination of hospital medical records, telephone contacts with patients or family members, and death registration at the Guangdong Provincial Center for Disease Control and Prevention.
From date of inclusion until the date of death from any cause, assessed up to 1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cardiovascular Mortality
Time Frame: From date of inclusion until the date of death from any cause, assessed up to 1 year
Cardiovascular mortality was defined as death attributable to an ischemic cardiovascular cause (including fatal MI, stroke).
From date of inclusion until the date of death from any cause, assessed up to 1 year

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Secondary outcomes of cardiovascular diseases
Time Frame: Through study completion, an average of 1 years
The number of and the incidence rate of cardiovascular diseases.
Through study completion, an average of 1 years
Secondary outcomes of cerebrovascular diseases
Time Frame: Through study completion, an average of 1 years
The incidence rate of cerebrovascular diseases.
Through study completion, an average of 1 years
Secondary outcomes of kidney
Time Frame: Through study completion, an average of 1 years
The incidence rate of hypertensive renal injure and end-stage renal disease
Through study completion, an average of 1 years
others
Time Frame: From date of inclusion until the date of first event, assessed up to 1 year
Number of participants with reported hospitalization due to other diseases(eg. diabetes， tumor)
From date of inclusion until the date of first event, assessed up to 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Guangdong Provincial People's Hospital

Investigators

  • Study Director: Feng Ying-qing, PhD, Guangdong Provincial People's Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2020

Primary Completion (Anticipated)

December 31, 2022

Study Completion (Anticipated)

December 31, 2050

Study Registration Dates

First Submitted

December 24, 2019

First Submitted That Met QC Criteria

December 24, 2019

First Posted (Actual)

December 27, 2019

Study Record Updates

Last Update Posted (Actual)

January 13, 2020

Last Update Submitted That Met QC Criteria

January 10, 2020

Last Verified

December 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2019343H(R2)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe